Chapter 2 Epidemiology of the Antiphospholipid Syndrome

Handbook of Systemic Autoimmune Diseases

Volumn 10, Issue , 2009, Pages 13-34

  Mehrani, Taraneh ^a,b   Petri, Michelle ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti beta 2 glycoprotein I; anticardiolipin; antiphospholipid syndrome; epidemiology; infection; lupus anticoagulant; malignancy; prevalence; systemic lupus erythematosus

Indexed keywords

EID: 67649803627     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(08)00402-9     Document Type: Review

References (147)

1. Abuaf N., Laperche S., Rajoely B., Carsique R., Deschamps A., Rouquette A.M., et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb. Haemost. 77 (1997) 856-861
2. Alarcon-Segovia D., Deleze M., Oria C.V., Sanchez-Guerrero J., Gomez-Pacheco L., Cabiedes J., et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68 (1989) 353-365
3. Alarcon-Segovia D., Perez-Vazquez M.E., Villa A.R., Drenkard C., and Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum. 21 (1992) 275-286
4. Allen J.Y., Tapia-Santiago C.T., and Kutteh W.H. Antiphospholipid antibodies in patients with preeclampsia. Am. J. Reprod. Immunol. 36 (1996) 81-85
5. Amin N.M. Antiphospholipid syndromes in infectious diseases. Hematol. Oncol. Clin. N. Am. 22 (2008) 131-143
6. APASS (The Antiphospholipid Antibodies in Stroke Study) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43 (1993) 2069-2073
7. APASS. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 48 (1997) 91-94
8. Asherson R.A. Antiphospholipid antibodies, malignancies and paraproteinemias. J. Autoimmun. 15 (2000) 117-122
9. Asherson R.A. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
10. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun. Rev. 6 (2006) 76-80
11. Asherson R.A., and Cervera R. Antiphospholipid antibodies and infections. Ann. Rheum. Dis. 62 (2003) 388-393
12. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 (1998) 195-207
13. Asherson R.A., Khamashta M.A., Ordi-Ros J., et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68 (1989) 366-374
14. Baker W.F., and Bick R.L. The clinical spectrum of antiphospholipid syndrome. Hematol. Oncol. Clin. N. Am. 22 (2008) 33-52
15. Bas de Laat H., Derksen R.H., and de Groot P.G. Beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin. Immunol. 112 (2004) 161-168
16. 2-glycoprotein I cause LA, and their presence correlates strongly with thrombosis. Blood 105 (2005) 1540-1545
17. Bas de Laat H., Derksen R.H., Urbanus R.T., Roest M., and de Groot P.G. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104 (2004) 3598-3602
18. Bas de Laat H., Mertens K., and de Groot P.G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nature Clin. Pract. Rheumatol. 4 (2008) 192-199
19. Beaumont JL. Syndrome hemorrhagic acquis du a un anticoagulant [French]. Sang 25 (1954) 1-5
20. Bertolaccini M.L., Atsumi T., Contreras A.E., Khamashta M.A., and Hughes G.R.V. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J. Rheumatol. 28 (2001) 2637-2643
21. Bertolaccini M.L., and Khamashta M.A. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 15 (2006) 172-178
22. Bick R.L., Jakway J., and Baker W.F. Deep venous thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin. Thromb. Hemost. 18 (1992) 267-274
23. Blank M., Asherson R.A., Cervera R., and Shoenfeld Y. Antiphospholipid syndrome infectious origin. J. Clin. Immunol. 24 (2004) 12-23
24. Bowie E.J., Thompson Jr. J.H., Pascuzzi C.A., and Owen Jr. C.A. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J. Lab. Clin. Med. 62 (1963) 416-430
25. Branch D.W., Andres R., Digre K.B., Rote N.S., and Scott J.R. The association of antiphospholipid antibodies with severe preeclampsia. Obstet. Gynecol. 73 (1989) 541-545
26. Branch D.W., Silver R.M., Blackwell J.L., Reading J.C., and Scott J.R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol. 80 (1992) 614-620
27. Brey R.L., Hart R.G., Sherman D.G., and Tegeler C.H. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 40 (1990) 1190-1196
28. Brouwer J.L., Bijl M., Veeger N.J., et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104 (2004) 143-148
29. Burn J., Dennis M., Bamford J., Sandercock P., Wade D., and Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 25 (1994) 333-337
30. Cabral, A., Cabiedes, J. 2007. Comments on the reassessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. e-letter.
31. Carmo-Pereira S., Bertolaccini M.L., Escudero-Contreras A., and Khamashta M.A. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann. Rheum. Dis. 62 (2003) 540-543
32. Carp H.J.A. Antiphospholipid syndrome in pregnancy. Curr. Opin. Obstet. Gynecol. 16, 129-135 (2004)
33. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb. Res. 114 (2004) 501-507
34. Cervera R. Lessons from the "Euro-phospholipid" project. Autoimmun. Rev. 7 (2008) 174-178
35. Cervera R., Asherson R.A., Acevedo M.L., Gomez-Puerta J.A., Espinoza G., and de la Red G. Antiphospholipid syndrome associated with infections: clinical and microbial characteristics of 100 patients. Ann. Rheum. Dis. 63 (2004) 1312-1317
36. Cervera R., Khamashta M.A., Font J., et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 72 (1993) 113-124
37. Cervera R., Piette J., Font J., et al. Antiphospholipid Syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 4 (2002) 1019-1027
38. Clowse M.E., Magder L., Witter F.R., and Petri M. Early risk factors for pregnancy loss in lupus. Obstet. Gynecol. 107 (2006) 293-299
39. Clowse M.E., Witter F.R., Magder L., and Petri M. The impact of increased lupus activity on obstetrical outcomes. Arthritis Rheum. 52 (2005) 514-521
40. Conley C.L., and Hartman R.C.A. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. Clin. Invest. 31 (1952) 621-622
41. Cooper R., Cutler J., Desvigne-Nickens P., Fortmann S.P., Friedman L., Morosco G., Mosca L., Pearson T., Stamler J., Stryer D., and Thom T. Trends and disparities in coronary heart disease, stroke, and other cardiovascular disease in the United States: findings of the national conference on heart disease prevention. Circulation 102 (2000) 3137-3147
42. Creagh M.D., Duncan S.L.B., McDonnell J.M., and Greaves M. Failure of the detection of antiphospholipid antibodies alone to predict poor pregnancy outcome. Br. J. Haematol. 77 (1991) 4
43. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N. Engl. J. Med. 349 (2003) 1133-1138
44. Cucurull E., Gharavi A.E., Diri E., Mendez E., Kapoor D., and Espinoza L.R. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am. J. Med. Sci. 318 (1999) 55-60
45. Dalekos G.N., Zachou K., and Liaskos C. The antiphospholipid syndrome and infection. Curr. Rheumatol. Rep. 3 (2001) 277-285
46. Danowski A., Kickler T.S., and Petri M. Anti-B2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J. Rheumatol. 33 (2006) 1775-1779
47. De Larranga G.F., Forasterio R.R., Carreras L.O., and Alonso B.S. Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome. Thromb. Res. 96 (1999) 19-25
48. Deschiens M., Conrad J., Horellou M., et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 27 (1996) 1724-1729
49. Diri E., Cucurull E., Gharavi A.E., Kapoor D., Mendez E.A., Scopelitis E., and Wilson W.A. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and anti-b2-glycoprotein I is the most frequent isotype. Lupus 9 (1999) 33-41
50. Diz-Kucukkaya R., Hacihanefioglu A., Yenerel M., Turgut M., Keskin H., Nalcaci M., and Inanc M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 98 (2001) 1760-1764
51. Duckitt K., and Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. Br. Med. J. 330 (2005) 565
52. Eschwege V., Peynaud-Debayle E., Wolf M., Amiral J., Vissac A.M., Bridey F., et al. Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis. Coagul. Fibrin. 9 (1998) 429-434
53. Faden D., Tincani A., Tanzi P., Spatola L., Lojacono A., Tarantini M., and Balestrieri G. Anti-beta 2 glycoprotein I antibodies in general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 73 (1997) 37-42
54. Fanopoulos D., Teodorescu M., Varga J., and Teodorescu M. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J. Rheumatol. 25 (1998) 675-680
55. Favaloro E., and Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am. J. Clin. Pathol. 118 (2002) 548-557
56. Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk?. Curr. Rheumatol. Rep. 3 (2001) 271-276
57. Finazzi G., Brancaccio V., Moia M., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med. 100 (1996) 530-536
58. Finazzi G., Marchioli R., Branaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3 (2005) 848-853
59. Fonollosa V., Selva A., Lima J., Simeon C.P., and Vilardell M. Anticardiolipin antibodies in systemic sclerosis. J. Am. Acad. Dermatol. 25 (1991) 133-134
60. Font J., Cervera R., Lopez-Soto A., et al. Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations. Clin. Rheumatol. 8 (1989) 475-483
61. Font J., Lopez-Soto A., Cervera R., Balasch J., Pallares L., Navarro M., et al. The primary antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 9 (1991) 69-75
62. Forasterio R., Martinuzzo M., Adamczuk Y., et al. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica 86 (2001) 735-741
63. Galli M., Finazzi G., and Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br. J. Haematol. 98 (1996) 1-5
64. Galli M., Luciani D., Bertolini G., and Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102 (2003) 2717-2723
65. Galli M., Luciani D., Bertolini G., and Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003) 1827-1832
66. Ginsberg K.S., Liang M.H., Newcomer L., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med. 117 (1992) 997-1002
67. Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C., Rodriguez-Martorell J., and Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J. Rheumatol. 31 (2004) 1560-1567
68. Glueck G.J., Lang J.E., Tracy T., Sieve-Smith L., and Wang P. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am. J. Cardiol. 83 (1999) 1490-1494
69. Gomez-Pacheco L., Villa A.R., Drenkard C., Cabiedes J., Cabral A.R., and Alarcon-Segovia D. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am. J. Med. 106 (1999) 417-423
70. Gulko P.S., Reveille J.D., Koopman W.J., Burgard S.L., Bartolucci A.A., and Alarcon G.S. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J. Rheumatol. 20 (1993) 1684-1693
71. Hanley J.G. Antiphospholipid syndrome: an overview. CMAJ 168 (2003) 1675-1682
72. Hart R.G., Miller V.T., Coull B.M., and Bril V. Cerebral infarction associated with lupus anticoagulants: preliminary report. Stroke 15 (1984) 114-118
73. Hess D.C., Krauss J., Adams R.J., Nichols F.T., Zhang D., and Rountree H.A. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 41 (1991) 525-528
74. Hughes G.R.V. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br. J. Med. 287 (1983) 1088-1089
75. Jouhikainen T., Stephansson E., and Leirisalo-Repo M. Lpus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br. J. Rheumatol. 32 (1993) 568-573
76. Juby A.G., and Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin. Invest. Med. 21 (1998) 4-11
77. Karmochkine M., Cacoub P., Dorent R., Laroche P., Nataf P., Piette J.C., et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J. Rheumatol. 23 (1996) 286-290
78. Kaul M.S., Erkan D., Sammaritano L.R., and Lockshin M.D. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. 66 (2007) 927-930
79. Khamashta M.A., and Hunt B.J. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome?. No. J. Thromb. Haemost. 3 (2005) 844-845
80. Krnic-Barrie S., O'Connor C.R., Looney S.W., Pierangeli S.S., and Harris E.N. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch. Intern. Med. 157 (1997) 2101-2108
81. Lai S.M., Alter M., Friday G., and Sobel E. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 25 (1994) 958-962
82. Lee E.Y., Lee C.K., Lee T.H., Chung S.M., Kim S.H., Cho Y.S., Yoo B., and Moon H.B. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?. Thromb. Res. 111 (2003) 29-32
83. Lee R.M., Brown M.A., Branch W., Ward K., and Silver R.M. Anticardiolipin and anti-B2-glycoprotein I antibodies in preeclampsia. Obstet. Gynecol. 102 (2003) 294-300
84. Lee S., Cho M., Joo Y., Kim W., Hong Y., Min J., et al. Isotypes of anti-b2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J. Rheumatol. 28 (2001) 520-524
85. Levine J.S., Branch W., and Rauch J. The antiphospholipid syndrome. N. Engl. J. Med. 346 (2002) 752-763
86. Levine S.R., Brey R.L., Joseph C.L.M., and Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 23 Suppl. I (1992) I29-I32
87. Levine S.R., Deegan M.J., Futrell N., and Welch K.M.A. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 40 (1990) 1181-1189
88. Lima F., Khamashta M.A., Buchanan N.M., Kerslake S., Hunt B.J., and Hughes G.R. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin. Exp. Rheumatol. 14 (1996) 131-136
89. Lockshin M.D., Druzin M.L., Goei S., Qamar T., Magid M.S., Jovanovic L., et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N. Engl. J. Med. 313 (1985) 152-156
90. Lockshin M.D., Sammaritano L.R., and Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 43 (2000) 440-443
91. Love P.E., and Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann. Intern. Med. 112 (1990) 682-698
92. Lynch A., Byers T., Emlen W., Rynes D., Shetterly S.M., and Hamman R.F. Association of antibodies to beta-2-glycoprotein I with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obstet. Gynecol. 93 (1999) 193-198
93. Mackworth-Young C., Loizou S., and Walport M. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann. Rheum. Dis. 48 (1989) 362-367
94. Male C., Foulon D., Hoogendoorn H., Vegh O., Silverman E., David M., and Mitchell L. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 106 (2005) 4152-4158
95. Manoussakis M.N., Tzioufas A.G., Silis M.P., Pange P.J.E., Goudevenos J., and Moutsopoulos H.M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin. Exp. Immunol. 69 (1987) 557-565
96. Mateo J., Oliver A., Borrell M., Sala N., and Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb. Hemost. 77 (1997) 444-451
97. Mengarelli A., Minotti C., Palumbo G., Arcieri P., Gentile G., Iori A.P., et al. High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogenic stem cell transplantation. Br. J. Haematol. 108 (2000) 126-131
98. Merkel P.A., Chang Y.C., Pierangeli S.S., Convery K., Harris E.N., and Polisson R.P. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am. J. Med. 101 (1996) 576-583
99. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., De Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., and Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4 (2006) 295-306
100. Molina J.F., Gutierrez-Urena S., Molina J., Uribe O., Richards S., De Ceulaer C., et al. Variability of anticardiolipin isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J. Rheumatol. 24 (1997) 291-296
101. Moore J.E., and Mohr G.F. Biologically false positive tests for syphilis: type, incidence, and cause. J. Am. Med. Assoc. 150 (1952) 467-473
102. Mouritsen S., Hoier-Madsen M., Wiik A., Orum O., and Strandberg Peterson N. The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 76 (1989) 178-183
103. Nencini P., Baruffi M.C., Abbate R., et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 23 (1992) 189-193
104. Opatrny L., David M., Kahn S.R., Shrier I., and Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J. Rheumatol. 33 (2006) 2214-2221
105. Pangborn M.C. A new serologically active phospholipid from beef heart. Proc. Soc. Exp. Biol. Med. 48 (1941) 484-486
106. Passaleva A., Massai G., Matucci-Cerinic M., Domeneghetti M.P., Sharifian J., Lotti T., et al. Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity 6 (1990) 283-291
107. Petri M. Epidemiology of the antiphospholipid syndrome. J. Autoimmun. 15 (2000) 145-151
108. Petri M. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J. Rheumatol. 31 (2004) 12
109. Petri M. Epidemiology of antiphospholipid syndrome. Hughes Syndrome. 2nd edn (2006), Springer, London 22-28
110. Petri M., Hochberg M., Hellman D., et al. Race and disease activity are associated with the presence of antiphospholipid antibody in systemic lupus erythematosus: a five-year prospective study [abstract]. Arthritis Rheum. 34 Suppl. (1991) S130
111. Pourrat O., Jollit C., Gombert J., Boinot C., and Pierre F. Clinical relevance of the recent update of the classification criteria for definite antiphospholipid syndrome: an obstetric medicine clinic series of 107 patients. J. Thromb. Haemost. 4 (2006) 2276-2277
112. Provenzale J.M., Ortel T.L., and Allen N.B. Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. AJR Am. J. Roentgenol. 170 (1998) 285-290
113. Reber G., Schousboe I., Tincani A., Sanmarco M., Kveder T., and Moerloose P. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaorative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb. Haemost. 88 (2002) 66-73
114. Rosove M.H., and Brewer P.M.C. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117 (1992) 303-308
115. Ruiz-Irastorza G., and Khamashta M.A. Antiphospholipid syndrome in pregnancy. Rheum. Dis. Clin. N. Am. 33 (2007) 287-297
116. Salomon O., Steinberg D.M., Zivelin A., Gitel S., Dardik R., Rosenberg N., et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 511-518
117. Samarkos M., Davies K.A., Gordon C., and Loizou S. Clinical significance of IgA anticardiolipin and anti-beta2-gp1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin. Rheumatol. 25 (2006) 199-204
118. Sammaritano L. Therapy Insight: guidelines for selection of contraception in women with rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3 (2007) 273-281
119. Sanna G., Bertolaccini M.L., Mameli A., Hughes G.R.V., Khamashta M.A., and Mathieu A. Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance. Ann. Rheum. Dis. 64 (2005) 1795-1796
120. Schulman S., Svenungsson E., Granqvist S., and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am. J. Med. 104 (1998) 332-338
121. Schved J.F., Dupuy-Fons C., Biron C., Quere I., and Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) study. Haemostasis 24 (1994) 175-182
122. Shi W., Krilis S.A., Chong B.H., Gordon S., and Chesterman C.N. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust. N. Z. J. Med. 20 (1990) 231-236
123. Silver R.M., Porter F., Van Leeuween I., et al. Clinical consequences of low titers. Obstet. Gynecol. 87 (1996) 494-500
124. Simpson J.L., Carson S.A., Chesney C., Conley M.R., Metzger B., Aarons J., et al. Lack of association between antiphospholipid antibodies and first-trimester spontaneous abortion: prospective study of pregnancies detected within 21 days of conception. Fertil. Steril. 69 (1998) 814-820
125. Sletnes K.E., Smith P., Abelnoor M., et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke. Lancet 1994 (1992) 452-456
126. Somers E., Magder L.S., and Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. J. Rheumatol. 29 (2002) 2531-2536
127. Tarr T., Lakos G., Bhattoa H.P., Soltesz P., Shoenfeld Y., Szegedi G., and Kiss E. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin. Rev. Allergy Immunol. 32 (2007) 131-137
128. Teixido M., Font J., Reverter J.C., Cervera R., Tassies D., Ingelmo M., et al. Anti-beta-2 glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. Br. J. Rheumatol. 36 (1997) 113-116
129. Tubach F., Hayem G., Marchand J.-L., et al. IgG anti-b2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J. Rheumatol. 27 (2000) 1437-1443
130. Turiel M., Sarzi-Puttini P., Peretti R., et al. Thrombotic risk factors in primary antiphospholipid syndrome. A 5-year prospective study. Stroke 36 (2005) 1490-1494
131. Vaarala O., Manttari M., Manninen V., Tenkanen L., Puurunen M., Aho K., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91 (1995) 23-27
132. Van Pampus M.G., Dekker G.A., Wolf H., Huijgens P.C., Koopman M.M.W., von Blomberg M.E., et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am. J. Obstet. Gynecol. 180 (1999) 1146-1150
133. Vianna J.L., Khamashta M.A., Ordi-Ros J., et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am. J. Med. 96 (1994) 3-9
134. Vila P., Hernandez M.C., Lopez-Fernandez M.F., and Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost. 72 (1994) 209-213
135. Wahl D.G., Guillemin F., De Maistre E., Perret-Guillaume C., Lecompte T., and Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 6 (1997) 467-473
136. Wahl D.G., Guillemin F., De Maistre E., Perret-Guillaume C., Lecompte T., and Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 7 (1998) 15-22
137. Wahl D.G., De Maistre E., Guillemin F., Regnault V., Perret-Guillaume C., and Lecompte T. Antibodies against phospholipids and beta-2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. QJM 91 (1998) 125-130
138. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 42 (1999) 1309-1311
139. Wong K.-L., Liu H.-W., Ho K., Chan K., and Wong R. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 18 (1991) 1187-1192
140. Wong R.C.W. Consensus guidelines for anticardiolipin antibody testing. Thromb. Res. 114 (2004) 559-571
141. Wu R., Nityanand S., Berglund L., Lithell H., Holm G., and Lefvert A.K. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict MI. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3159-3163
142. Yasuda M., Takakuwa K., Tokunaga A., and Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet. Gynecol. 86 (1995) 555-559
143. Zanon E., Prandoni P., Vianello F., Saggiorato G., Carraro G., Bagatella P., et al. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb. Res. 96 (1999) 269-274
144. Zavaleta N.E., Montes R.M., Soto M.E., Vanzzini N.A., and Amigo M.C. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow-up study. J. Rheumatol. 31 (2004) 2402-2407
145. Zielinska J., Ryglewicz D., Wierzchowska E., Lechowicz W., Hier D.B., and Czlonkowska A. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol. Res. 21 (1999) 653-657
146. Zoghlami-Rintelen C., Vormittag R., Sailer T., Lehr S., Quehenberger P., Rumpold H., Male. C., and Pabinger I. The presence of IgG antibodies against anti-B2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J. Thromb. Haemost. 3 (2005) 1160-1165
147. Zuckerman E., Toubi E., Golan T.D., Rosenvald-Zuckerman T., Sabo E., Shmuel Z., and Yeshurun D. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br. J. Cancer 72 (1995) 447-451